ClinicalTrials.gg

Program

MRNA-1195

A development code. Also written as “mRNA-1195”, “mRNA-1195.1” and “mRNA-1195.2”.

Its studies are mostly in Epstein-Barr Virus Infections · Multiple Sclerosis, led by Moderna.

Furthest: phase 2, since Dec 11, 20242 company-led studies, 1 open or runningNext primary completion: Jan 8, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moderna21 open or runningphase 2since Dec 11, 2024Apr 14, 2023Jan 8, 2029phase 2 · NCT06735248

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2023First study: phase 1 study in Epstein-Barr Virus InfectionsFirst studyNCT05831111 · 482 enrolled · United States
  2. Dec 11, 2024Phase 2 study in Multiple SclerosisNCT06735248 · 180 planned · United States, Australia, United Kingdom

Ahead

  1. Jan 8, 2029Primary completion: phase 2 study in Multiple SclerosisNCT06735248

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06735248Multiple Sclerosis · United States, Australia, United Kingdom2RecruitingJan 8, 2029180
NCT05831111Epstein-Barr Virus Infections · United States1CompletedOct 14, 2026482

How it is read

Names in the registry

  • “mRNA-1195”, 2 entries
  • “mRNA-1195.1”, 1 entry
  • “mRNA-1195.2”, 1 entry

Codes read as this program: MRNA1195.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
MRNA-1195 (Moderna): development program | ClinicalTrials.gg